Subchronic toxicity of silica nanoparticles as a function of size and porosity.


Journal

Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908

Informations de publication

Date de publication:
28 06 2019
Historique:
received: 08 02 2019
revised: 20 04 2019
accepted: 28 04 2019
pubmed: 3 5 2019
medline: 10 9 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

Despite increasing reports of using silica nanoparticles (SNPs) for controlled drug delivery applications, their long-term toxicity profile following intravenous administration remains unexplored. Herein, we investigated the acute (10-day) and subchronic (60-day and 180-day) toxicity of nonporous SNPs of approximately 50 nm (Stöber SNPs50) and approximately 500 nm in diameter (Stöber SNPs500), and mesoporous SNPs of approximately 500 nm in diameter (MSNPs500) upon single-dose intravenous injection into male and female immune-competent inbred BALB/c mice. The Maximum Tolerated Dose (MTD) of the particles was determined 10 days post-injection. The MTD of SNPs was administered and toxicity evaluated over 60 and 180 days. Results demonstrate that Stöber SNPs50 exhibit systemic toxicity with MTD of 103 ± 11 mg.kg

Identifiants

pubmed: 31047961
pii: S0168-3659(19)30244-5
doi: 10.1016/j.jconrel.2019.04.041
pmc: PMC6681828
mid: NIHMS1531305
pii:
doi:

Substances chimiques

Cytokines 0
Silicon Dioxide 7631-86-9

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

216-232

Subventions

Organisme : NIDCR NIH HHS
ID : R01 DE019050
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES024681
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Front Immunol. 2014 Oct 07;5:491
pubmed: 25339958
J Pharmacol Pharmacother. 2011 Apr;2(2):74-9
pubmed: 21772764
Eur J Pharm Biopharm. 2009 Aug;72(3):626-9
pubmed: 19341796
J Biol Chem. 2016 Jul 1;291(27):14170-14184
pubmed: 27226546
ACS Nano. 2010 Feb 23;4(2):699-708
pubmed: 20088598
Front Biosci. 1997 Jan 01;2:d12-26
pubmed: 9159205
ACS Appl Mater Interfaces. 2016 Dec 21;8(50):34820-34832
pubmed: 27998138
Acc Chem Res. 2007 Sep;40(9):846-53
pubmed: 17645305
Cardiovasc Res. 2008 Aug 1;79(3):360-76
pubmed: 18487233
Part Fibre Toxicol. 2018 May 21;15(1):23
pubmed: 29783987
Int J Nanomedicine. 2013;8:147-58
pubmed: 23326190
ACS Nano. 2011 May 24;5(5):4131-44
pubmed: 21524062
Nanomedicine. 2018 Feb;14(2):533-545
pubmed: 29203145
Biomaterials. 2015;53:574-82
pubmed: 25890753
J Virol. 1994 Aug;68(8):5126-32
pubmed: 8035512
J Control Release. 2011 Jul 15;153(1):40-8
pubmed: 21342660
ACS Nano. 2011 Jul 26;5(7):5717-28
pubmed: 21630682
Methods Mol Biol. 2012;926:235-53
pubmed: 22975969
J Am Chem Soc. 2007 Jul 18;129(28):8845-9
pubmed: 17589996
Acta Pharm Sin B. 2018 Mar;8(2):165-177
pubmed: 29719777
Chem Soc Rev. 2015 Jul 21;44(14):4645-71
pubmed: 25406516
J Pharmacol Exp Ther. 2019 Sep;370(3):751-760
pubmed: 30442652
Arch Toxicol. 2017 Sep;91(9):2967-3010
pubmed: 28573455
Int J Nanomedicine. 2014 Dec 15;9 Suppl 2:67-78
pubmed: 25565827
J Control Release. 2012 Oct 10;163(1):46-54
pubmed: 22684119
ACS Nano. 2011 Jul 26;5(7):5390-9
pubmed: 21634407
Adv Drug Deliv Rev. 2018 Nov - Dec;136-137:82-96
pubmed: 30273617
PLoS One. 2013 Apr 12;8(4):e61346
pubmed: 23593469
Toxicol Mech Methods. 2016 May;26(4):260-9
pubmed: 27055490
Nanomedicine. 2019 Feb;16:106-125
pubmed: 30529789
Toxicol Rep. 2018 May 23;5:632-638
pubmed: 30622900
ACS Nano. 2012 Mar 27;6(3):2289-301
pubmed: 22364198
Arch Toxicol. 2010 Mar;84(3):183-90
pubmed: 19936708
Small. 2011 Jan 17;7(2):271-80
pubmed: 21213393
J Immunol. 1984 Feb;132(2):656-61
pubmed: 6228595
Nanotoxicology. 2012 Nov;6(7):713-23
pubmed: 21793770
ACS Appl Bio Mater. 2018 Nov 19;1(5):1620-1627
pubmed: 34046558
ACS Appl Mater Interfaces. 2017 Jun 28;9(25):21133-21146
pubmed: 28609092
Toxicol Lett. 2009 Sep 28;189(3):177-83
pubmed: 19397964
ACS Nano. 2013 Mar 26;7(3):1961-73
pubmed: 23402533
J Immunol. 1979 Dec;123(6):2568-74
pubmed: 159320
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271

Auteurs

Raziye Mohammadpour (R)

Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, United States.

Mostafa Yazdimamaghani (M)

Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, United States.

Darwin L Cheney (DL)

Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, United States.

Jolanta Jedrzkiewicz (J)

Department of Pathology, University of Utah, Salt Lake City, UT, United States.

Hamidreza Ghandehari (H)

Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah, Salt Lake City, UT, United States; Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, United States; Department of Bioengineering, University of Utah, Salt Lake City, UT, United States. Electronic address: hamid.ghandehari@utah.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH